Solid support matricles containing a toxin binding oligosaccharide

A solid support matrix of the formula:

• ##STR8## wherein SS is a solid support;
• R.sup.1 is selected from the group consisting of a covalent bond and a hydrocarbylene group having from 1 to about 20 carbon atoms;
• R.sup.3 is selected from the group consisting of hydrogen and --C(O)R.sup.5 wherein R.sup.5 is elected from the group consisting of hydrogen and hydrocarbyl of from 1 to 20 carbon atoms;
• R.sup.6 is an alkylene group of from 4 to 10 carbon atoms.
• Z is toxin-binding oligosaccharide, and
• n is an integer such that the matrix has a loading level of the toxin-binding oligosaccharide of from about 0.001 to about 2000 .mu.moles per gram of solid support
• wherein the total number of atoms separating the solid support from the toxin- binding oligosaccharide is at least 8.

A pharmaceutical composition useful for in vivo treatment of a toxin-mediated disease in a mammal, which composition comprises a pharmaceutically acceptable carrier suitable for oral administration and a solid support matrix of the formula:

• ##STR9## wherein SS is a solid support;
• R.sup.1 is selected from the group consisting of a covalent bond and a hydrocarbylene group having from I to about 20 carbon atoms;
• R.sup.2 is a hydrocarbylene group of from 2 to 20 carbon atoms;
• each X' is independently selected from the group consisting of --O-- and>NR.sup.4 wherein each R.sup.4 is independently selected from hydrogen, R.sup.2 NH.sub.2 or R.sup.2 NR.sup.3 Z wherein R.sup.2 is as defined above;
• R.sup.3 is selected from the group consisting of hydrogen and --C(O)R.sup.5 wherein R.sup.5 is selected from the group consisting of hydrogen and hydrocarbyl of from 1 to 20 carbon atoms;
• W is selected from oxygen or sulfur;
• X is selected from the group consisting of --NH--, --O-- and --S--;
• Y is selected from the group consisting of --NH--, --O-- and --S--;
• Z is toxin-binding oligosaccharide;
• p is an integer from 0 to 50;
• and
• n is an integer such that the matrix has a loading level of the toxin-binding oligosaccharide of from about 0.001 to about 2000 .mu.moles per gram of solid support
• wherein the total number of atoms separating the solid support from the toxin-binding oligosaccharide is at least 8
• wherein the matrix is capable of being eliminated from the gastrointestinal tract.

A pharmaceutical composition useful for in vivo treatment of a toxin-mediated disease in a mammal, which composition comprises a pharmaceutically acceptable carrier suitable for oral administration and a solid support matrix of the formula ##STR10## wherein SS is a solid support;

• R.sup.1 is selected from the group consisting of a covalent bond and a hydrocarbylene group having from 1 to about 20 carbon atoms;
• R.sup.3 is selected from the group consisting of hydrogen and --C(O)R.sup.5 wherein R.sup.5 is selected from the group consisting of hydrogen and hydrocarbyl of from 1 to 20 carbon atoms;
• R.sup.6 is an alkylene group of from 4 to 10 carbon atoms.
• Z is toxin-binding oligosaccharide, and
• n is an integer such that the matrix has a loading level of the toxin-binding oligosaccharide of from about 0,001 to about 2000 .mu.moles per gram of solid support
• wherein the total number of atoms separating the solid support from the toxin-binding oligosaccharide is at least 8
• wherein the matrix is capable of being eliminated from the gastrointestinal tract.